WO2019212202A1 - Composition pour la protection du foie comprenant un extrait de curcuma et un extrait fermenté de soja et de germes de riz - Google Patents

Composition pour la protection du foie comprenant un extrait de curcuma et un extrait fermenté de soja et de germes de riz Download PDF

Info

Publication number
WO2019212202A1
WO2019212202A1 PCT/KR2019/005066 KR2019005066W WO2019212202A1 WO 2019212202 A1 WO2019212202 A1 WO 2019212202A1 KR 2019005066 W KR2019005066 W KR 2019005066W WO 2019212202 A1 WO2019212202 A1 WO 2019212202A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
food composition
turmeric extract
rice
study
Prior art date
Application number
PCT/KR2019/005066
Other languages
English (en)
Korean (ko)
Inventor
전준호
박형근
백남준
유재영
조성모
Original Assignee
동아제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아제약 주식회사 filed Critical 동아제약 주식회사
Publication of WO2019212202A1 publication Critical patent/WO2019212202A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms

Definitions

  • the present invention relates to a composition containing turmeric extract and rice soybean fermented extract, and more particularly, to a composition for liver protection containing turmeric extract and rice soybean fermented extract.
  • the mixture of turmeric extract and rice soybean fermented extract has effects such as liver damage protection, fatty liver suppression and hangover relief which are superior to their respective single substances.
  • Alcohol intake not only causes major organ and human cell disorders in the body's metabolic processes but also can have a very fatal effect on the major organs of the body such as the gastrointestinal tract, brain, nerves, endocrine organs, pancreas, hematopoietic organs, immune system, and liver tissue. It will cause a fatal damage to the structure and function of the.
  • Alcohol dehydrogenase ADH
  • Acetaldehyde is acetic acid and hydrogen by the catalytic reaction of aldehyde dehydrogenase (ALDH).
  • a hangover is a common phenomenon experienced by most people who consume alcohol. It causes headaches, vomiting, heartburn, tiredness and diarrhea, and it causes social and economic losses as well as physical discomfort for the person experiencing the hangover. Nevertheless, the exact cause of the hangover has not been precisely identified, but it is estimated to be closely related to blood alcohol or acetaldehyde concentration. Accordingly, it is speculated that rapid alcohol decomposition is necessary to reduce the hangover symptoms. In addition, excessive alcohol consumption can lead to liver damage of alcohol-related diseases such as alcoholic fatty liver, alcoholic hepatitis and cirrhosis in addition to hangovers.
  • Alcoholic liver disease is the first disease that occurs after alcohol abuse and is characterized by fat accumulation in liver cells. Alcoholic liver disease is caused by a variety of complex mechanisms, which occur in four steps: First, the production of nicotinamide adenine dinucleotide (NADH) by the oxidation of alcohol, the increase in the synthesis of triglycerides and fatty acids, the inhibition of mitochondrial ⁇ -oxidation of fatty acids occurs. Second, the influx of free fatty acids from adipose tissue to the liver is increased, and the influx of chylomicron from visceral mucosa is increased.
  • NADH nicotinamide adenine dinucleotide
  • adenosine monophosphate-activated protein kinase via ethanol is inhibited, resulting in increased lipid biosynthesis and inhibition of PPAR ⁇ (peroxisome proliferator-activated receptor ⁇ ) and SREBP1c.
  • PPAR ⁇ peroxisome proliferator-activated receptor ⁇
  • SREBP1c peroxisome proliferator-activated receptor ⁇
  • Lipolysis decreases as the (sterol regulatory element binding protein 1c) is activated.
  • mitochondria and microtubules are damaged by acetaldehyde, resulting in reduced NADH oxidation and accumulation of very low density lipoprotein (VLDL).
  • VLDL very low density lipoprotein
  • Curcuma longa L is the root stem of perennial Curcuma aromatic SALISB.
  • Pharmacological action is known to promote bile secretion, uterine excitability, blood pressure lowering, analgesic action. It has the effect of inhibiting the development of Staphylococcus aureus, fungi, etc., and has been demonstrated to reduce hyperlipidemia.
  • Turmeric is grown mainly in rainy subtropics, from southern China to Southeast Asia. It grows wild in the forests of South and Southeast Asia. Turmeric contains 4.5% of essential oils and contains turmerone, zingerene, phellandrene and cineole.
  • the present inventors have conducted a long study to develop a therapeutic material that has an excellent effect on the recovery of liver disease and liver damage without side effects, and when using a combination of turmeric extract and fermented rice soybean extract, they are superior to those used alone.
  • the present invention was found to exhibit excellent effects.
  • An object of the present invention is to provide a composition for liver protection containing turmeric extract and rice eye soybean fermented extract as an active ingredient.
  • the mixture of turmeric extract and rice soybean fermented extract has effects such as liver damage protection, fatty liver suppression and hangover resolution which are superior to their respective single substances.
  • the present invention provides a composition for liver protection containing turmeric extract and rice eye soybean fermented extract as an active ingredient. Specifically, the present invention relates to a food composition for the prevention or improvement of liver damage, fatty liver or hangover, including turmeric extract and rice soybean fermented extract.
  • the present invention relates to a food composition
  • a food composition comprising turmeric extract and rice soybean fermented extract in a weight ratio of 1: 1 to 1:15.
  • the average particle size of the turmeric extract may be 500 to 1,500 nm for solubilization of the turmeric extract.
  • Turmeric extract of the present invention may be prepared by a method comprising the following steps:
  • step 2) grinding the mixture of step 1) with a liquid mill
  • step 3 filtering and sterilizing the ultrafine pulverized product of step 3).
  • the thickener and the emulsifier are mixed with the turmeric extract powder to ensure homogeneity.
  • the thickener may be gati gum, arivia gum, guar gum, tamarind gum, carrageenan, pectin, agar, locust bean gum, alginic acid or carboxymethylcellulose sodium, preferably gati gum.
  • the emulsifier may be glycerin, glycerin fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, propylene glycol fatty acid ester, soybean, lecithin, saponin or polysorbate, preferably glycerin.
  • Rice bran soybean fermented extract of the present invention may be prepared by a method comprising the following steps:
  • step 2) fermenting and extracting the mixture of step 1) by microorganisms
  • step 4) Sterilizing the concentrate of step 3) through microfilter filtration.
  • the microorganism used to prepare the rice bran soybean fermentation extract of the present invention may be one or more microorganisms selected from the group consisting of Saccharomyces genus and Issatchenkia genus, but is not limited thereto.
  • Saccharomyces genus microorganism may be at least one microorganism selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces bolladi and Saccharomyces bayanus.
  • the Issatchenkia genus microorganism may be one or more microorganisms selected from the group consisting of Ischenchen orientalis, Ischenchenia oxydetalis, Ischenchenia skuturata, and Isschenchia telicoila. Can be.
  • the present invention may be a food composition for preventing or improving liver damage, fatty liver, or hangover, including turmeric extract and fermented rice soybean extract.
  • the food composition may be a dietary supplement, dairy product, fermented product or food additive, but is not limited thereto.
  • the mixture of turmeric extract and rice bran soybean fermentation extract of the present invention in liver model (D-galactosamin hepatitis model, CCl 4 liver injury model, and alcohol fatty liver model) compared to using turmeric extract or rice bran soybean fermentation extract alone
  • Representative hepatic indicators AST, ALT and lipid reduction, showing excellent effects can be useful as a composition such as liver protection, liver function improvement and hangover relief.
  • the mixture of turmeric extract and rice bran soybean fermentation extract of the present invention has no side effects, it can have the effect of preventing or improving liver damage and fatty liver when taken for a long time.
  • Figure 1 shows the results of measuring the ALT level in carbon tetrachloride-induced liver injury mice.
  • Figure 2 shows the results of measuring the AST level in carbon tetrachloride-induced liver injury mice.
  • Figure 3 shows the results of measuring the ALT level in carbon tetrachloride-induced liver injury mice.
  • Figure 4 shows the results of measuring the AST level in carbon tetrachloride-induced liver injury mice.
  • Figure 5 shows the results of measuring the ALT level in D-galactosamine-induced liver injury rat model.
  • Figure 6 shows the results of measuring the AST level in the liver-damaged rat model induced by D-galactosamine.
  • Figure 7 shows the results of measuring the T-CHO level in the liver-damaged rat model induced by D-galactosamine.
  • Figure 8 shows the results of measuring the TG value in D-galactosamine-induced liver injury rat model.
  • Figure 9 shows the results of measuring the ALT level in a chronic alcohol rat model.
  • Figure 10 shows the results of measuring the AST level in a chronic alcohol rat model.
  • Figure 11 shows the results of measuring the T-CHO level in the chronic alcohol rat model.
  • Figure 12 shows the results of measuring the TG level in chronic alcohol rat model.
  • Figure 13 shows hepatocyte pictures through Oil-red O staining in chronic alcohol rat model.
  • the present invention provides a composition for liver protection containing turmeric extract and rice bran soybean fermentation extract as an active ingredient.
  • Turmeric extract of the present invention is preferably solubilized by the following method, but is not limited thereto:
  • step 2) grinding the mixture of step 1) with a liquid mill
  • step 3 filtering and sterilizing the ultrafine pulverized product of step 3).
  • turmeric extract powder may be included in 1-20% by weight, glycerin, 1-30% by weight, 1-10% by weight of Gaticomm, and 5-80% by weight of purified water.
  • Turmeric extract of the present invention preferably has an average particle size of 500 to 1,500nm, but is not limited thereto.
  • Rice eye soybean fermentation extract of the present invention is preferably prepared by the following method, but is not limited thereto:
  • step 2) fermenting and extracting the mixture of step 1) by microorganisms
  • step 4) Sterilizing the concentrate of step 3) through microfilter filtration.
  • the fermented soybean extract of the present invention is preferably fermented by one or more microorganisms selected from the group consisting of Saccharomyces genus and Issatchenkia genus, but is not limited thereto.
  • Saccharomyces sp. Microorganism may be at least one microorganism selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces bolladi and Saccharomyces bayanus, but is not limited thereto.
  • the genus of Issachenia microorganism may be one or more microorganisms selected from the group consisting of Issachenia orientalis, Isachenchia oxydetalis, Isachenchia skuturata and Isachenchia telicola, but are not limited thereto .
  • composition of the present invention can be used in medicines, health foods, dairy products, fermented products and food additives.
  • the composition of the present invention may be administered in unit form such as tablets, capsules, solutions, suspensions, etc. obtained by mixing with a carrier, excipient, or diluent selected according to the route of administration.
  • Suitable carriers, excipients and diluents for the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polysilicate. Vinylpyrrolidone, cellulose, syrup, methylcellulose, methyl and propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like.
  • composition does not necessarily mean to be approved as a medicine, but is a concept including a general functional food or a dietary supplement.
  • Turmeric composition of the present invention was prepared by the following method.
  • Turmeric extract powder was mixed in a ratio of 12% by weight, glycerin 20% by weight, Gattigum 2% by weight, and 66% by weight of purified water, and then the mixture was ground with a liquid grinder.
  • the pulverized product was pulverized with a super mill and then filtered through a 400mesh Stan filter network. The filtrate was sterilized at 65 ° C. for 30 minutes to prepare a turmeric composition.
  • Rice snow soybean fermentation extract of the present invention was prepared by the following method. 40 g of rice snow, 30 g of skim rice bran, 4 g of soybean peptide, 5 g of phytic acid, 10 g of sodium hydrogen phosphate, 2.5 g of potassium hydrogen phosphate, 15 g of glucose, and 0.25 g of antifoam were added to 500 g of water. 0.05% (w / w) of protease was added to the mixture and stirred to mix the raw materials. Saccharomyces cerevisiae 1% (w / w) was inoculated to the medium and stirred for 48 hours at 30 ⁇ 40 °C. The culture was treated with activated carbon and filtered through diatomaceous earth. The filtrate was concentrated to concentrate the content of solids to about 30% to prepare a rice bran soybean fermentation extract.
  • mice were treated with C57BL / 6 mice (25-35 g), normal (normal), carbon tetrachloride (CCl 4 ) and animals treated with hepatotoxicity.
  • the experiment was carried out by dividing rice snow soybean fermented extract and turmeric extract into a group of 9 groups (Study 1 ⁇ 7, mixed ratio). After oral administration of the test drug five times for a total of five days, hepatotoxicity was intraperitoneally administered with CCl 4 (0.2%, 10mg / kg). After separation, only plasma was recovered and ALT and AST were measured by blood biochemical analysis. The results are shown in Table 1, FIG. 1 and FIG. 2.
  • CCl 4 Short-term administration of CCl 4 is widely used to cause experimental liver damage and liver fibrosis.
  • the exact mechanism by which CCl 4 causes liver damage and hepatic fibrosis is not known yet, but the role of CCl 4 as a pro-oxidant is important. That is, CCl 4 forms trichloromethyl free radicals in the hepatic microsomal cytochrome P-450, resulting in trichloromethylperoxy radicals, which directly or indirectly damage lipids or other molecules in the cell membrane.
  • ALT of the rice bran soybean fermented extract administration group (Study 1) was reduced by about 18% (p ⁇ 0.05) and AST by about 17% (p ⁇ 0.05) compared to the control group.
  • ALT of turmeric extract administration group (Study 2) decreased by about 42% and AST by about 40% compared to the control group (p ⁇ 0.01).
  • ALT and AST in both the rice soybean fermented extract and turmeric extract group decreased by about 45% (p ⁇ 0.01), so that the rice snow soybean fermented extract and turmeric extract group (Study 3) Compared to the single-dose group of (Study 1) and turmeric extract administration group (Study 2), half of each of the single-dose group was administered, but it was confirmed that it had a much better effect.
  • Hepatotoxicity was induced by intraperitoneal administration of D-galactosamine. A total of four doses were administered with doses of 600 mg / kg on day 0, day 2, 700 mg / kg on day 4, and 800 mg / kg on day 6. Hepatotoxicity was induced. Drug treatment was administered orally (10 ml / kg) every day from the day of hepatotoxicity to the end of the test. The test period was 14 days after the autopsy, blood was collected from the abdominal aorta, centrifuged at 1,500 rpm for 15 minutes, and only plasma was recovered. The targets were AST, ALT and T-CHO and TG, which are indicators of liver damage. Blood biochemical analysis was performed.
  • D-galactosamine is toxic to hepatocytes, and when administered to experimental animals, it causes fat change, inflammatory cell response and hepatocellular necrosis of hepatocytes and induces lesions similar to viral hepatitis.
  • D-GalN D-galactosamine
  • hepatic necrosis in case of acute poisoning of D-GalN, cirrhosis and cellular tumors in case of chronic poisoning.
  • uridine phosphate compounds are depleted during galactose metabolism in hepatocytes, resulting in inhibition of uridine metabolism, resulting in abnormal RNA and protein synthesis, resulting in altered cell membrane permeability, resulting in large amounts of calcium It is known that necrosis of hepatocytes occurs as it enters.
  • AST a major marker of liver damage
  • ALT, T-CHO and TG values were measured, shown in Table 3 and Table 4, Figures 5-8.
  • ALT of the rice bran soybean fermented extract administration group (Study 1) was reduced by about 29% (p ⁇ 0.05) compared to the control group, and the AST was about 10% (p ⁇ 0.05).
  • ALT of the turmeric extract group (Study 2) decreased by 36% (p ⁇ 0.01) and AST by 20% (p ⁇ 0.01).
  • T-CHO and TG of the rice bran soybean fermentation extract administration group (Study 1) tended to decrease by about 10%, but there was no statistical significance.
  • T-CHO of turmeric extract group showed a tendency to decrease by about 15%, but there was no significance, and TG decreased by about 21% (p ⁇ 0.01).
  • T-CHO and TG in the mixed administration group of rice soybean fermented extract and turmeric extract both decreased by about 35% and statistical significance was recognized.
  • the mixed administration group (Study 3) of rice bran soybean fermentation extract and turmeric extract have a superior effect on lipid reduction compared to the single administration group of rice bran soybean fermentation extract (Study 1) and turmeric extract group (Study 2). It could be confirmed that having.
  • the experimental animals used in this experiment were divided into 5 groups of 10 rats after 1 week of adaptation to Sprague-Dawley male SD rats (DBL, Eumseong, Korea) with an average body weight of about 200 g.
  • the diet was divided into two groups: normal (normal group) and ethanol-containing feed group.
  • Ethanol-containing feed group was Control (control), rice snow soybean fermented extract group (Study 1, 80 mg / kg), turmeric extract group (Study 2, 50 mg / kg), rice snow soybean fermented extract and turmeric extract (Study 3, fermented soybean extract 40 mg / kg, turmeric extract 25 mg / kg), divided into 5 groups, and after 5 days alcohol diet adaptation period, and based on the 10 days Lieber-Decali Diet 5% (v / v) EtOH liquid diet was used as feed. Each test substance was assigned to alcohol feed according to the group. Nine days after the oral administration of 30% alcohol on the 11th day of the test, a necropsy was performed to extract liver and serum, and serum was analyzed for AST, ALT, and lipid change, T-CHO. , Blood biochemical analysis was performed on TG, and liver tissues were identified by fatty staining with alcohol through fat-staining Oil-red O staining, and the results are shown in Tables 5 and 6 and FIGS. 9 to 16.
  • Chronic alcohol intake causes disorders such as pancreatitis, myocardial infarction, neuropathy, and tuberculosis, and further causes fatal damage to liver structure and function.
  • the ALT of the rice bran soybean fermented extract administration group is reduced by about 20% (p ⁇ 0.05) and AST by about 16% (p ⁇ 0.05) compared to the control group.
  • ALT decreased by about 34% (p ⁇ 0.01) and AST by about 30% (p ⁇ 0.01).
  • ALT was significantly reduced to 46% (p ⁇ 0.01) and AST was 36% (p ⁇ 0.01) in the mixed-administered rice soybean fermented extract and turmeric extract (Study 3), and the mixture of rice-soybean fermented extract and turmeric extract It was confirmed that the administration group (Study 3) has a superior effect compared to the single-dose group of the rice eye soybean fermentation extract administration group (Study 1) and turmeric extract administration group (Study 2).
  • T-CHO of the rice bran soybean fermented extract administration group (Study 1) showed a decrease of about 9% compared to the control group, but statistical significance And TG decreased by about 18% (p ⁇ 0.05).
  • T-CHO of turmeric extract administration group (Study 2) decreased about 34% (p ⁇ 0.05) and TG about 38% (p ⁇ 0.05).
  • the T-CHO and TG in the mixed administration group (Study 3) of rice bran soybean fermentation extract and turmeric extract was reduced by about 40%, it was confirmed that the superior effect on lipid reduction compared to the single administration group.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention a pour objet une composition destinée à la protection du foie contenant un extrait de curcuma et un extrait fermenté de soja et de germes de riz en tant que principes actifs. Spécifiquement, le mélange d'extrait de curcuma et d'extrait fermenté de soja et de germes de riz a des effets tels que la protection des lésions du foie, la suppression de la stéatose hépatique et le soulagement de la veisalgie qui sont bien supérieurs à chacune des substances de celui-ci.
PCT/KR2019/005066 2018-04-30 2019-04-26 Composition pour la protection du foie comprenant un extrait de curcuma et un extrait fermenté de soja et de germes de riz WO2019212202A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180049915A KR102648340B1 (ko) 2018-04-30 2018-04-30 강황추출물 및 쌀눈대두 발효추출물을 포함하는 간보호용 조성물
KR10-2018-0049915 2018-04-30

Publications (1)

Publication Number Publication Date
WO2019212202A1 true WO2019212202A1 (fr) 2019-11-07

Family

ID=68385958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/005066 WO2019212202A1 (fr) 2018-04-30 2019-04-26 Composition pour la protection du foie comprenant un extrait de curcuma et un extrait fermenté de soja et de germes de riz

Country Status (2)

Country Link
KR (1) KR102648340B1 (fr)
WO (1) WO2019212202A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102642811B1 (ko) * 2021-01-18 2024-03-05 한국과학기술연구원 콩비지 미세분말 기반의 숙취 해소용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001786A1 (fr) * 2007-06-22 2008-12-31 Kaneka Corporation Composition contenant une substance physiologiquement active
KR20120123860A (ko) * 2011-05-02 2012-11-12 보해양조주식회사 숙취해소 또는 간 기능 개선용 조성물
KR101247927B1 (ko) * 2012-07-16 2013-03-26 보령제약 주식회사 숙취 예방 또는 해소용 조성물
KR101324431B1 (ko) * 2013-05-14 2013-10-31 주식회사 한국인삼공사 숙취해소용 조성물
KR20160081500A (ko) * 2014-12-31 2016-07-08 주식회사 풀무원 아스파라거스, 울금추출물, 미배아대두발효추출물을 포함하는 숙취해소용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101296995B1 (ko) * 2013-02-15 2013-08-14 주식회사 엠에스씨 발효 쌀겨 및 미배아를 락토바실러스속 미생물에 의해 발효시킨 발효물 및 이의 제조방법
KR101808406B1 (ko) * 2016-02-23 2017-12-14 심희영 강황, 미강을 이용한 건강기능식품의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001786A1 (fr) * 2007-06-22 2008-12-31 Kaneka Corporation Composition contenant une substance physiologiquement active
KR20120123860A (ko) * 2011-05-02 2012-11-12 보해양조주식회사 숙취해소 또는 간 기능 개선용 조성물
KR101247927B1 (ko) * 2012-07-16 2013-03-26 보령제약 주식회사 숙취 예방 또는 해소용 조성물
KR101324431B1 (ko) * 2013-05-14 2013-10-31 주식회사 한국인삼공사 숙취해소용 조성물
KR20160081500A (ko) * 2014-12-31 2016-07-08 주식회사 풀무원 아스파라거스, 울금추출물, 미배아대두발효추출물을 포함하는 숙취해소용 조성물

Also Published As

Publication number Publication date
KR20190125735A (ko) 2019-11-07
KR102648340B1 (ko) 2024-03-18

Similar Documents

Publication Publication Date Title
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2010058926A2 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
WO2010137846A2 (fr) Composition pour accroître de la biodisponibilité de la saponine
WO2014069874A1 (fr) Composition permettant d'éliminer des substances kératiniques de la peau comprenant des lactobacillus de thé vert
WO2022131428A1 (fr) Composition comprenant de l'orlistat et une souche d'akkermansia muciniphila eb-amdk19
WO2013047958A1 (fr) Composition pour inhiber une détérioration de la fonction hépatique, contenant un extrait d'écorce de citrus ou du narirutin comme ingrédient actif, et procédé pour extraire du narirutin à partir d'écorce de citrus
WO2019212202A1 (fr) Composition pour la protection du foie comprenant un extrait de curcuma et un extrait fermenté de soja et de germes de riz
WO2017183902A1 (fr) Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie
WO2019117654A1 (fr) Probiotiques pour inhiber et prévenir l'évolution de maladies rénales et compositions pour inhiber et prévenir l'évolution de maladies rénales les comprenant
WO2017176001A1 (fr) Composition destinée à soulager les symptômes de la ménopause chez les femmes, contenant de l'extrait de sasa quelpaertensis nakai
WO2021091164A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter l'obésité ou l'allergie comprenant un extrait de rose comme ingrédient actif
WO2016076607A2 (fr) Composition pharmaceutique et aliment fonctionnel pour la santé, contenant un concentré de ginseng rouge avec un composé enrichi en composant k, pour la prévention et le traitement du symptôme de la stéatose hépatique d'origine non alcoolique
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
WO2020085799A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie hépatique, comprenant un extrait de platycodon grandiflorum standardisé contenant de la sapopnine de platycodon grandiflorum ou un extrait de saponine de platycodon grandiflorum séparé par membrane et aliment fonctionnel de santé pour l'amélioration de la fonction hépatique
WO2018131780A1 (fr) Composition destinée à prévenir ou à traiter la gastrite ou l'ulcère gastroduodénal
WO2022211396A1 (fr) Composition pharmaceutique incluant un extrait de salvia plebeia r. br. ou un composé dérivé de celui-ci en tant que principe actif pour la prévention ou le traitement de la dystrophie musculaire
WO2014133286A1 (fr) Composition contenant des extraits d'artemisia iwayomogi et de curcuma longa en tant que principes actifs pour la prévention, l'inhibition ou le traitement de maladies se rapportant à l'obésité
WO2014133276A1 (fr) Composition contenant, en tant que composants actifs, menispermum dauricum, un extrait de menispermum dauricum, un biofilm de menispermum dauricum, ou un extrait de liquide enzymatique de malt de menispermum dauricum pour prévenir ou traiter l'anorexie
WO2012138076A2 (fr) Composition contenant un mélange d'extraits végétaux pour la prévention ou le traitement de maladies gastro-intestinales
WO2021070999A1 (fr) Composition destinée à la prévention, à l'amélioration ou au traitement de syndromes métaboliques y compris l'obésité, le diabète, une hyperlipidémie et la stéatose hépatique
WO2019156335A1 (fr) Composition pharmaceutique destinée au traitement de la stéatose hépatique et aliment fonctionnel de santé destiné à l'amélioration de la fonction hépatique, les deux contenant un extrait ou une poudre de pleurotus eryngii var. ferulae en tant que principe actif
WO2020141778A1 (fr) Composition comprenant de la séricine pour le traitement, la prévention ou le soulagement d'une stéatose hépatique, et son procédé de préparation
WO2020004858A1 (fr) Composition pour soulager le diabète ou antioxydante comprenant un extrait de levure et procédé de préparation d'extrait de levure
WO2023022244A1 (fr) Composition de protection du foie ou de prévention ou d'amélioration d'une maladie hépatique
WO2019245245A1 (fr) Composition pharmaceutique pour la prévention et le traitement d'une lésion hépatique comprenant un extrait de curcuma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19796356

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19796356

Country of ref document: EP

Kind code of ref document: A1